About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 474605, 13 pages
http://dx.doi.org/10.1155/2012/474605
Review Article

Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy

1Adjuvant Unit, Department of Pharmacy and Pharmaceutical Technology, and Department of Microbiology, University of Navarra, 31008 Pamplona, Spain
2Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, 31008 Pamplona, Spain

Received 1 September 2011; Revised 19 October 2011; Accepted 25 October 2011

Academic Editor: Alf Månsson

Copyright © 2012 Juliana De Souza Rebouças et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Martino and S. L. Prescott, “Silent mysteries: epigenetic paradigms could hold the key to conquering the epidemic of allergy and immune disease,” Allergy, vol. 65, no. 1, pp. 7–15, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. H. Sicherer and H. A. Sampson, “Peanut allergy: emerging concepts and approaches for an apparent epidemic,” Journal of Allergy and Clinical Immunology, vol. 120, no. 3, pp. 491–503, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. P. G. H. Gell and R. R. A. Coombs, Clinical Aspects of Immunology, Blackwell, Oxford, UK, 1st edition, 1963.
  4. J. O. Warner, M. A. Kaliner, C. D. Crisci et al., “Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council,” International Archives of Allergy and Immunology, vol. 139, no. 2, pp. 166–174, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. P. Grammatikos, “The genetic and environmental basis of atopic diseases,” Annals of Medicine, vol. 40, no. 7, pp. 482–495, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. D. Vercelli, “Discovering susceptibility genes for asthma and allergy,” Nature Reviews Immunology, vol. 8, no. 3, pp. 169–182, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. C. Ober, S. A. Leavitt, A. Tsalenko et al., “Variation in the interleukin 4-receptor α gene confers susceptibility to asthma and atopy in ethnically diverse populations,” American Journal of Human Genetics, vol. 66, no. 2, pp. 517–526, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. G. M. Hunninghake, M. E. Soto-Quirós, L. Avila et al., “Polymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhood,” Journal of Allergy and Clinical Immunology, vol. 120, no. 1, pp. 84–90, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. X. Liu, T. H. Beaty, P. Deindl et al., “Associations between specific serum IgE response and 6 variants within the genes IL4, IL13, and IL4RA in German children: the German Multicenter Atopy Study,” Journal of Allergy and Clinical Immunology, vol. 113, no. 3, pp. 489–495, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. L. O'Mahony, M. Akdis, R. Crameri, and C. A. Akdis, “Novel immunotherapeutic approaches for allergy and asthma,” Autoimmunity, vol. 43, no. 7, pp. 493–503, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. N. Novak, “New insights into the mechanism and management of allergic diseases: atopic dermatitis,” Allergy, vol. 64, no. 2, pp. 265–275, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. V. Niederberger and R. Valenta, “Molecular approaches for new vaccines against allergy,” Expert Review of Vaccines, vol. 5, no. 1, pp. 103–110, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. M. Rolland, L. M. Gardner, and R. E. O'Hehir, “Allergen-related approaches to immunotherapy,” Pharmacology and Therapeutics, vol. 121, no. 3, pp. 273–284, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. G. Pauli and H. J. Malling, “The current state of recombinant allergens for immunotherapy,” Current Opinion in Allergy and Clinical Immunology, vol. 10, no. 6, pp. 575–581, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. T. Strait, S. C. Morris, and F. D. Finkelman, “IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and FcγRIIb cross-linking,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 833–841, 2006. View at Publisher · View at Google Scholar · View at PubMed
  16. Y. Ma, K. T. Hayglass, A. B. Becker et al., “Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice,” Allergy, vol. 62, no. 6, pp. 675–682, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. Y. Ma, K. T. HayGlass, A. B. Becker et al., “Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 5, pp. 439–445, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. P. Pulsawat, S. Piboonpocanun, S. Sirivichayakul et al., “Production and immunogenicity of hypoallergenic codon-optimized DNA vaccine encoding mature Der p 1 allergen,” Journal of Investigational Allergology and Clinical Immunology, vol. 20, no. 7, pp. 582–590, 2010.
  19. G. K. Gupta and D. K. Agrawal, “CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma,” BioDrugs, vol. 24, no. 4, pp. 225–235, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. D. I. Bernstein, T. Epstein, K. Murphy-Berendts, and G. M. Liss, “Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI Collaborative Study,” Annals of Allergy, Asthma and Immunology, vol. 104, no. 6, pp. 530–535, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. S. Broos, K. Lundberg, T. Akagi et al., “Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: implications for specific immunotherapy,” Vaccine, vol. 28, no. 31, pp. 5075–5085, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. R. Klippstein and D. Pozo, “Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies,” Nanomedicine, vol. 6, no. 4, pp. 523–529, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. I. Schöll, G. Boltz-Nitulescu, and E. Jensen-Jarolim, “Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy,” Journal of Controlled Release, vol. 104, no. 1, pp. 1–27, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. S. Romagnani, “Immunologic influences on allergy and the TH1/TH2 balance,” Journal of Allergy and Clinical Immunology, vol. 113, no. 3, pp. 395–400, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. D. S. Robinson, “Th-2 cytokines in allergic disease,” British Medical Bulletin, vol. 56, no. 4, pp. 956–968, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. M. I. Araujo, R. A. Campos, L. S. Cardoso, S. C. Oliveira, and E. M. Carvalho, “Immunomodulation of the allergic inflammatory response: new developments,” Inflammation and Allergy—Drug Targets, vol. 9, no. 2, pp. 73–82, 2010. View at Scopus
  27. Y. Zhao, J. Yang, and Y.-D. Gao, “Altered expressions of helper T cell (Th)1, Th2, and Th17 cytokines in CD8+ and γδ T cells in patients with allergic asthma,” Journal of Asthma, vol. 48, no. 5, pp. 429–436, 2011. View at Publisher · View at Google Scholar · View at PubMed
  28. O. Palomares, G. Yaman, A. K. Azkur, T. Akkoc, M. Akdis, and C. A. Akdis, “Role of Treg in immune regulation of allergic diseases,” European Journal of Immunology, vol. 40, no. 5, pp. 1232–1240, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. K. Oboki, T. Ohno, H. Saito, and S. Nakae, “Th17 and allergy,” Allergology International, vol. 57, no. 2, pp. 121–134, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. J. Frew, “Allergen immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 125, no. 2, pp. S306–S313, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. R. Valenta and D. Kraft, “From allergen structure to new forms of allergen-specific immunotherapy,” Current Opinion in Immunology, vol. 14, no. 6, pp. 718–727, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. S. J. Till, J. N. Francis, K. Nouri-Aria, and S. R. Durham, “Mechanisms of immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 113, no. 6, pp. 1025–1034, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. M. Larché, C. A. Akdis, and R. Valenta, “Immunological mechanisms of allergen-specific immunotherapy,” Nature Reviews Immunology, vol. 6, no. 10, pp. 761–771, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. G. Ciprandi, G. L. Marseglia, and M. A. Tosca, “Allergen-specific immunotherapy: an update on immunological mechanisms of action,” Monaldi Archives for Chest Disease, vol. 65, no. 1, pp. 34–37, 2006. View at Scopus
  35. C. A. Akdis and M. Akdis, “Mechanisms and treatment of allergic disease in the big picture of regulatory T cells,” Journal of Allergy and Clinical Immunology, vol. 123, no. 4, pp. 735–746, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. M. Akdis and C. A. Akdis, “Therapeutic manipulation of immune tolerance in allergic disease,” Nature Reviews Drug Discovery, vol. 8, no. 8, pp. 645–660, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. D. I. Bernstein, T. Epstein, K. Murphy-Berendts, and G. M. Liss, “Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI Collaborative Study,” Annals of Allergy, Asthma and Immunology, vol. 104, no. 6, pp. 530–535, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. R. Roy, J. R. Sigmon, J. Olivier, J. E. Moffitt, D. A. Brown, and G. D. Marshall, “Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy,” Annals of Allergy, Asthma and Immunology, vol. 99, no. 1, pp. 82–86, 2007. View at Scopus
  39. G. W. Canonica and G. Passalacqua, “Noninjection routes for immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 111, no. 3, pp. 437–448, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Ozdemir, “An immunological overview of allergen specific immunotherapy—subcutaneous and sublingual routes,” Therapeutic Advances in Respiratory Disease, vol. 3, no. 5, pp. 253–262, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. G. W. Canonica, J. Bousquet, T. Casale et al., “Sub-lingual immunotherapy: world allergy organization position paper 2009,” Allergy, vol. 64, no. 91, pp. 1–59, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. J. Bousquet, R. Lockey, H. J. Malling et al., “Allergen immunotherapy: therapeutic vaccines for allergic diseases—a WHO position paper,” Journal of Allergy and Clinical Immunology, vol. 102, no. 4, pp. 558–562, 1998. View at Scopus
  43. W. Wang and M. Singh, “Selection of adjuvants for enhanced vaccine potency,” World Journal of Vaccines, vol. 1, pp. 33–78, 2011.
  44. J. N. Francis and S. R. Durham, “Adjuvants for allergen immunotherapy: experimental results and clinical perspectives,” Current Opinion in Allergy and Clinical Immunology, vol. 4, no. 6, pp. 543–548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. A. W. Wheeler and S. R. Woroniecki, “Immunological adjuvants in allergy vaccines: past, present and future,” Allergology International, vol. 50, no. 4, pp. 295–301, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. J. C. Aguilar and E. G. Rodríguez, “Vaccine adjuvants revisited,” Vaccine, vol. 25, no. 19, pp. 3752–3762, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. Y. Perrie, A. R. Mohammed, D. J. Kirby, S. E. McNeil, and V. W. Bramwell, “Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens,” International Journal of Pharmaceutics, vol. 364, no. 2, pp. 272–280, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. A. des Rieux, V. Fievez, M. Garinot, Y. J. Schneider, and V. Préat, “Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach,” Journal of Controlled Release, vol. 116, no. 1, pp. 1–27, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. R. K. Gupta, “Aluminum compounds as vaccine adjuvants,” Advanced Drug Delivery Reviews, vol. 32, no. 3, pp. 155–172, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. A. C. Allison and G. Gregoriadis, “Liposomes as immunological adjuvants,” Nature, vol. 252, no. 5480, article 252, 1974.
  51. G. De Becker, V. Moulin, B. Pajak et al., “The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells,” International Immunology, vol. 12, no. 6, pp. 807–815, 2000. View at Scopus
  52. I. Schöll, G. Boltz-Nitulescu, and E. Jensen-Jarolim, “Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy,” Journal of Controlled Release, vol. 104, no. 1, pp. 1–27, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. H. Tighe, K. Takabayashi, D. Schwartz et al., “Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity,” Journal of Allergy and Clinical Immunology, vol. 106, no. 1, pp. 124–134, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. M. K. Tulic, P. O. Fiset, P. Christodoulopoulos et al., “Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response,” Journal of Allergy and Clinical Immunology, vol. 113, no. 2, pp. 235–241, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. S. Broos, K. Lundberg, T. Akagi et al., “Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: implications for specific immunotherapy,” Vaccine, vol. 28, no. 31, pp. 5075–5085, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. J. Kreuter, “Nanoparticles,” in Encyclopaedia of Pharmaceutical Technology, J. Swarbrick and J. C. Boylan, Eds., vol. 10, pp. 165–190, Marcel Dekker, New York, NY, USA, 1994.
  57. P. Couvreur, G. Barratt, E. Fattal, P. Legrand, and C. Vauthier, “Nanocapsule technology: a review,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 19, no. 2, pp. 99–134, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Kumari, S. K. Yadav, and S. C. Yadav, “Biodegradable polymeric nanoparticles based drug delivery systems,” Colloids and Surfaces B, vol. 75, no. 1, pp. 1–18, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. N. Csaba, M. Garcia-Fuentes, and M. J. Alonso, “Nanoparticles for nasal vaccination,” Advanced Drug Delivery Reviews, vol. 61, no. 2, pp. 140–157, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. T. Madan, N. Munshi, T. K. De, A. Maitra, P. Usha Sarma, and S. S. Aggarwal, “Biodegradable nanoparticles as a sustained release system for the antigens/allergens of Aspergillus fumigatus: preparation and characterisation,” International Journal of Pharmaceutics, vol. 159, no. 2, pp. 135–147, 1997. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Aggarwal, J. B. Hall, C. B. McLeland, M. A. Dobrovolskaia, and S. E. McNeil, “Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy,” Advanced Drug Delivery Reviews, vol. 61, no. 6, pp. 428–437, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. M. A. Dobrovolskaia, P. Aggarwal, J. B. Hall, and S. E. McNeil, “Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution,” Molecular Pharmaceutics, vol. 5, no. 4, pp. 487–495, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. M. A. Dobrovolskaia and S. E. McNeil, “Immunological properties of engineered nanomaterials,” Nature Nanotechnology, vol. 2, no. 8, pp. 469–478, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. M. Kalkanidis, G. A. Pietersz, S. D. Xiang et al., “Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity,” Methods, vol. 40, no. 1, pp. 20–29, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. J. C. Gautier, J. L. Grangier, A. Barbier et al., “Biodegradable nanoparticles for subcutaneous administration of growth hormone releasing factor (hGRF),” Journal of Controlled Release, vol. 20, no. 1, pp. 67–77, 1992. View at Publisher · View at Google Scholar · View at Scopus
  66. P. Couvreur, et al., “Biodegradable polymeric nanoparticles as drug carrier for antitumor agents,” in Polymeric Nanoparticles and Microspheres, P. Guiot and P. Couvreur, Eds., pp. 27–93, CRC Press, Boca Raton, Fla, USA, 1986.
  67. V. W. Bramwell and Y. Perrie, “Particulate delivery systems for vaccines: what can we expect?” Journal of Pharmacy and Pharmacology, vol. 58, no. 6, pp. 717–728, 2006. View at Publisher · View at Google Scholar · View at PubMed
  68. J. M. Irache, I. Esparza, C. Gamazo, M. Agüeros, and S. Espuelas, “Nanomedicine: novel approaches in human and veterinary therapeutics,” Veterinary Parasitology, vol. 180, no. 1-2, pp. 47–71, 2011. View at Publisher · View at Google Scholar · View at PubMed
  69. K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski, “Biodegradable polymeric nanoparticles as drug delivery devices,” Journal of Controlled Release, vol. 70, no. 1-2, pp. 1–20, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. L. J. Peek, C. R. Middaugh, and C. Berkland, “Nanotechnology in vaccine delivery,” Advanced Drug Delivery Reviews, vol. 60, no. 8, pp. 915–928, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. R. C. Mundargi, V. R. Babu, V. Rangaswamy, P. Patel, and T. M. Aminabhavi, “Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives,” Journal of Controlled Release, vol. 125, no. 3, pp. 193–209, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. H. Tamber, P. Johansen, H. P. Merkle, and B. Gander, “Formulation aspects of biodegradable polymeric microspheres for antigen delivery,” Advanced Drug Delivery Reviews, vol. 57, no. 3, pp. 357–376, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. A. G. A. Coombes, E. C. Lavelle, P. G. Jenkins, and S. S. Davis, “Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen,” Vaccine, vol. 14, no. 15, pp. 1429–1438, 1996. View at Publisher · View at Google Scholar · View at Scopus
  74. I. D. Spiers, J. E. Eyles, L. W. J. Baillie, E. D. Williamson, and H. O. Alpar, “Biodegradable microparticles with different release profiles: effect on the immune response after a single administration via intranasal and intramuscular routes,” Journal of Pharmacy and Pharmacology, vol. 52, no. 10, pp. 1195–1201, 2000. View at Scopus
  75. M. Igartua, R. M. Hernández, A. Esquisabel, A. R. Gascón, M. B. Calvo, and J. L. Pedraz, “Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres,” Journal of Controlled Release, vol. 56, no. 1–3, pp. 63–73, 1998. View at Publisher · View at Google Scholar · View at Scopus
  76. J. H. Eldrige, J. K. Staas, J. A. Meulbroek, J. R. McGhee, T. R. Tice, and R. M. Gilley, “Biodegradable microspheres as a vaccine delivery system,” Molecular Immunology, vol. 28, no. 3, pp. 287–294, 1991. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Combadière and B. Mahé, “Particle-based vaccines for transcutaneous vaccination,” Comparative Immunology, Microbiology and Infectious Diseases, vol. 31, no. 2-3, pp. 293–315, 2008. View at Publisher · View at Google Scholar · View at PubMed
  78. H. Sun, K. G. J. Pollock, and J. M. Brewer, “Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro,” Vaccine, vol. 21, no. 9-10, pp. 849–855, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Clawson, C. T. Huang, D. Futalan et al., “Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity,” Nanomedicine, vol. 6, no. 5, pp. 651–661, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. C. S. W. Chong, M. Cao, W. W. Wong et al., “Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery,” Journal of Controlled Release, vol. 102, no. 1, pp. 85–99, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. I. Schöll, G. Boltz-Nitulescu, and E. Jensen-Jarolim, “Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy,” Journal of Controlled Release, vol. 104, no. 1, pp. 1–27, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. I. Schöll, T. Kopp, B. Bohle, and E. Jensen-Jarolim, “Biodegradable PLGA particles for improved systemic and mucosal treatment of Type I allergy,” Immunology and Allergy Clinics of North America, vol. 26, no. 2, pp. 349–364, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. I. Schöll, A. Weissenböck, E. Förster-Waldl et al., “Allergen-loaded biodegradable poly(D,L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model,” Clinical and Experimental Allergy, vol. 34, no. 2, pp. 315–321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. C. D. Partidos, P. Vohra, D. H. Jones, G. Farrar, and M. W. Steward, “Induction of cytotoxic T-cell responses following oral immunization with synthetic peptides encapsulated in PLG microparticles,” Journal of Controlled Release, vol. 62, no. 3, pp. 325–332, 1999. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Batanero, P. Barral, M. Villalba, and R. Rodríguez, “Biodegradable poly (DL-lactide glycolide) microparticles as a vehicle for allergen-specific vaccines: a study performed with Ole e 1, the main allergen of olive pollen,” Journal of Immunological Methods, vol. 259, no. 1-2, pp. 87–94, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. A. I. Camacho, R. Da Costa Martins, I. Tamayo et al., “Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators,” Vaccine, vol. 29, no. 41, pp. 7130–7135, 2011. View at Publisher · View at Google Scholar · View at PubMed
  87. P. Johansen, Y. Men, H. P. Merkle, and B. Gander, “Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 129–146, 2000. View at Publisher · View at Google Scholar · View at Scopus
  88. S. K. Mallapragada and B. Narasimhan, “Immunomodulatory biomaterials,” International Journal of Pharmaceutics, vol. 364, no. 2, pp. 265–271, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. M. Murillo, C. Gamazo, J. M. Irache, and M. M. GoÑi, “Polyester microparticles as a vaccine delivery system for brucellosis: influence of the polymer on release, phagocytosis and toxicity,” Journal of Drug Targeting, vol. 10, no. 3, pp. 211–219, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. M. L. Hans and A. M. Lowman, “Biodegradable nanoparticles for drug delivery and targeting,” Current Opinion in Solid State and Materials Science, vol. 6, no. 4, pp. 319–327, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Vila, H. Gill, O. McCallion, and M. J. Alonso, “Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density,” Journal of Controlled Release, vol. 98, no. 2, pp. 231–244, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  92. D. J. Bharali, V. Pradhan, G. Elkin et al., “Novel nanoparticles for the delivery of recombinant hepatitis B vaccine,” Nanomedicine, vol. 4, no. 4, pp. 311–317, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. A. Vila, A. Sánchez, M. Tobío, P. Calvo, and M. J. Alonso, “Design of biodegradable particles for protein delivery,” Journal of Controlled Release, vol. 78, no. 1–3, pp. 15–24, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Vila, A. Sánchez, C. Évora, I. Soriano, O. McCallion, and M. J. Alonso, “PLA-PEG particles as nasal protein carriers: the influence of the particle size,” International Journal of Pharmaceutics, vol. 292, no. 1-2, pp. 43–52, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. V. R. Sinha, K. Bansal, R. Kaushik, R. Kumria, and A. Trehan, “Poly-ε-caprolactone microspheres and nanospheres: an overview,” International Journal of Pharmaceutics, vol. 278, no. 1, pp. 1–23, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. S. R. Jameela, N. Suma, A. Misra, R. Raghuvanshi, S. Ganga, and A. Jayakrishnan, “Poly(ε-caprolactone) microspheres as a vaccine carrier,” Current Science, vol. 70, no. 7, pp. 669–671, 1996. View at Scopus
  97. H. F. Florindo, S. Pandit, L. Lacerda, L. M. D. Gonçalves, H. O. Alpar, and A. J. Almeida, “The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-ε-caprolactone-based nanoparticles,” Biomaterials, vol. 30, no. 5, pp. 879–891, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. P. Arbós, M. A. Arangoa, M. A. Campanero, and J. M. Irache, “Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles,” International Journal of Pharmaceutics, vol. 242, no. 1-2, pp. 129–136, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. K. Vandamme, V. Melkebeek, E. Cox et al., “Influence of reaction medium during synthesis of Gantrez® AN 119 nanoparticles for oral vaccination,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 74, no. 2, pp. 202–208, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. P. Arbós, M. A. Campanero, M. A. Arangoa, M. J. Renedo, and J. M. Irache, “Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties,” Journal of Controlled Release, vol. 89, no. 1, pp. 19–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. H. H. Salman, C. Gamazo, M. A. Campanero, and J. M. Irache, “Salmonella-like bioadhesive nanoparticles,” Journal of Controlled Release, vol. 106, no. 1-2, pp. 1–13, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. K. Yoncheva, S. Gómez, M. A. Campanero, C. Gamazo, and J. M. Irache, “Bioadhesive properties of pegylated nanoparticles,” Expert Opinion on Drug Delivery, vol. 2, no. 2, pp. 205–218, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. S. Gómez, C. Gamazo, B. S. Roman, M. Ferrer, M. L. Sanz, and J. M. Irache, “Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens,” Vaccine, vol. 25, no. 29, pp. 5263–5271, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. S. Gómez, C. Gamazo, B. San Roman et al., “A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne,” Journal of Immunological Methods, vol. 348, no. 1-2, pp. 1–8, 2009. View at Publisher · View at Google Scholar · View at PubMed
  105. S. Gómez, C. Gamazo, B. S. Roman, C. Vauthier, M. Ferrer, and J. M. Irache, “Development of a novel vaccine delivery system based on gantrez nanoparticles,” Journal of Nanoscience and Nanotechnology, vol. 6, no. 9-10, pp. 3283–3289, 2006. View at Publisher · View at Google Scholar
  106. J. M. Irache, H. H. Salman, S. Gomez, S. Espuelas, and C. Gamazo, “Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination,” Frontiers in Bioscience, vol. 2, pp. 876–890, 2010.
  107. J. Ochoa, J. M. Irache, I. Tamayo, A. Walz, V. G. DelVecchio, and C. Gamazo, “Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice,” Vaccine, vol. 25, no. 22, pp. 4410–4419, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. I. Tamayo, J. M. Irache, C. Mansilla, J. Ochoa-Repáraz, J. J. Lasarte, and C. Gamazo, “Poly(anhydride) nanoparticles act as active Th1 adjuvants through toll-like receptor exploitation,” Clinical and Vaccine Immunology, vol. 17, no. 9, pp. 1356–1362, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  109. T. Akagi, T. Kaneko, T. Kida, and M. Akashi, “Preparation and characterization of biodegradable nanoparticles based on poly(γ-glutamic acid) with L-phenylalanine as a protein carrier,” Journal of Controlled Release, vol. 108, no. 2-3, pp. 226–236, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. S. Broos, K. Lundberg, T. Akagi et al., “Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: implications for specific immunotherapy,” Vaccine, vol. 28, no. 31, pp. 5075–5085, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. T. Uto, T. Akagi, K. Yoshinaga, M. Toyama, M. Akashi, and M. Baba, “The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway,” Biomaterials, vol. 32, no. 22, pp. 5206–5212, 2011. View at Publisher · View at Google Scholar · View at PubMed
  112. B. S. Zolnik, Á. González-Fernández, N. Sadrieh, and M. A. Dobrovolskaia, “Minireview: nanoparticles and the immune system,” Endocrinology, vol. 151, no. 2, pp. 458–465, 2010. View at Publisher · View at Google Scholar · View at PubMed
  113. D. H. Lee and I. J. Kang, “Drug delivery system using biodegradable nanoparticles carrier,” Kona, vol. 24, pp. 159–166, 2006.
  114. R. Jayakumar, N. Nwe, S. Tokura, and H. Tamura, “Sulfated chitin and chitosan as novel biomaterials,” International Journal of Biological Macromolecules, vol. 40, no. 3, pp. 175–181, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. L. Illum, I. Jabbal-Gill, M. Hinchcliffe, A. N. Fisher, and S. S. Davis, “Chitosan as a novel nasal delivery system for vaccines,” Advanced Drug Delivery Reviews, vol. 51, no. 1–3, pp. 81–96, 2001. View at Publisher · View at Google Scholar · View at Scopus
  116. K. Bowman and K. W. Leong, “Chitosan nanoparticles for oral drug and gene delivery,” International Journal of Nanomedicine, vol. 1, no. 2, pp. 117–128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Masotti and G. Ortaggi, “Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery,” Mini-Reviews in Medicinal Chemistry, vol. 9, no. 4, pp. 463–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. K. Nagpal, S. K. Singh, and D. N. Mishra, “Chitosan nanoparticles: a promising system in novel drug delivery,” Chemical and Pharmaceutical Bulletin, vol. 58, no. 11, pp. 1423–1430, 2010. View at Publisher · View at Google Scholar
  119. I. M. Van der Lubben, J. C. Verhoef, G. Borchard, and H. E. Junginger, “Chitosan for mucosal vaccination,” Advanced Drug Delivery Reviews, vol. 52, no. 2, pp. 139–144, 2001. View at Publisher · View at Google Scholar · View at Scopus
  120. G. Borchard, “Chitosans for gene delivery,” Advanced Drug Delivery Reviews, vol. 52, no. 2, pp. 145–150, 2001. View at Publisher · View at Google Scholar · View at Scopus
  121. H. L. Jiang, Y. K. Kim, R. Arote et al., “Chitosan-graft-polyethylenimine as a gene carrier,” Journal of Controlled Release, vol. 117, no. 2, pp. 273–280, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  122. W. E. Rudzinski and T. M. Aminabhavi, “Chitosan as a carrier for targeted delivery of small interfering RNA,” International Journal of Pharmaceutics, vol. 399, no. 1-2, pp. 1–11, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  123. A. V. Il'ina and V. P. Varlamov, “Chitosan-based polyelectrolyte complexes: a review,” Applied Biochemistry and Microbiology, vol. 41, no. 1, pp. 5–11, 2005. View at Publisher · View at Google Scholar
  124. A. Vila, A. Sánchez, K. Janes et al., “Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 57, no. 1, pp. 123–131, 2004. View at Publisher · View at Google Scholar
  125. K. Roy, H. Q. Mao, S. K. Huang, and K. W. Leong, “Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy,” Nature Medicine, vol. 5, no. 4, pp. 387–391, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  126. F. Li, L. Wang, X. M. Jin, C. H. Yan, S. Jiang, and X. M. Shen, “The immunologic effect of TGF-beta1 chitosan nanoparticle plasmids on ovalbumin-induced allergic BALB/c mice,” Immunobiology, vol. 214, no. 2, pp. 87–99, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  127. S. Zhu, F. Qian, Y. Zhang, C. Tang, and C. Yin, “Synthesis and characterization of PEG modified N-trimethylaminoethylmethacrylate chitosan nanoparticles,” European Polymer Journal, vol. 43, no. 6, pp. 2244–2253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. S. A. Agnihotri, N. N. Mallikarjuna, and T. M. Aminabhavi, “Recent advances on chitosan-based micro- and nanoparticles in drug delivery,” Journal of Controlled Release, vol. 100, no. 1, pp. 5–28, 2004. View at Publisher · View at Google Scholar · View at PubMed
  129. A. Domard, M. Rinaudo, and C. Terrassin, “New method for the quaternization of chitosan,” International Journal of Biological Macromolecules, vol. 8, no. 2, pp. 105–107, 1986.
  130. A. F. Kotze, M. M. Thanou, H. L. Luessen, A. B. G. De Boer, J. C. Verhoef, and H. E. Junginger, “Effect of the degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2),” European Journal of Pharmaceutics and Biopharmaceutics, vol. 47, no. 3, pp. 269–274, 1999. View at Publisher · View at Google Scholar
  131. S. Mangal, D. Pawar, N. K. Garg et al., “Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally,” Vaccine, vol. 29, no. 31, pp. 4953–4962, 2011. View at Publisher · View at Google Scholar · View at PubMed
  132. O. Borges, G. Borchard, J. C. Verhoef, A. De Sousa, and H. E. Junginger, “Preparation of coated nanoparticles for a new mucosal vaccine delivery system,” International Journal of Pharmaceutics, vol. 299, no. 1-2, pp. 155–166, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. O. Borges, M. Silva, A. de Sousa, G. Borchard, H. E. Junginger, and A. Cordeiro-da-Silva, “Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen,” International Immunopharmacology, vol. 8, no. 13-14, pp. 1773–1780, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  134. O. Borges, J. Tavares, A. de Sousa, G. Borchard, H. E. Junginger, and A. Cordeiro-da-Silva, “Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles,” European Journal of Pharmaceutical Sciences, vol. 32, no. 4-5, pp. 278–290, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. J. Ho, F. M. N. Al-Deen, A. Al-Abboodi et al., “N,N'-Carbonyldiimidazole-mediated functionalization of superparamagnetic nanoparticles as vaccine carrier,” Colloids and Surfaces B, vol. 83, no. 1, pp. 83–90, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  136. T. Fifis, A. Gamvrellis, B. Crimeen-Irwin et al., “Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors,” Journal of Immunology, vol. 173, no. 5, pp. 3148–3154, 2004. View at Scopus
  137. R. Song and C. V. Harding, “Roles of proteasomes, transporter for antigen presentation (TAP), and β2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway,” Journal of Immunology, vol. 156, no. 11, pp. 4182–4190, 1996. View at Scopus
  138. L. Vidard, M. Kovacsovics-Bankowski, S. K. Kraeft, L. B. Chen, B. Benacerraf, and K. L. Rock, “Analysis of MHC class II presentation of particulate antigens by B lymphocytes,” Journal of Immunology, vol. 156, no. 8, pp. 2809–2818, 1996. View at Scopus
  139. L. Zhang, G. Widera, S. Bleecher, D. A. Zaharoff, B. Mossop, and D. Rabussay, “Accelerated immune response to DNA vaccines,” DNA and Cell Biology, vol. 22, no. 12, pp. 815–822, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  140. D. M. Mahvi, F. S. Shi, N. S. Yang et al., “Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study,” Human Gene Therapy, vol. 13, no. 14, pp. 1711–1721, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  141. S. Parween, P. K. Gupta, and V. S. Chauhan, “Induction of humoral immune response against PfMSP-119 and PvMSP-119 using gold nanoparticles along with alum,” Vaccine, vol. 29, no. 13, pp. 2451–2460, 2011. View at Publisher · View at Google Scholar · View at PubMed
  142. Y. J. Kwon, S. M. Standley, S. L. Goh, and J. M. J. Fréchet, “Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles,” Journal of Controlled Release, vol. 105, no. 3, pp. 199–212, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  143. Y. J. Kwon, E. James, N. Shastri, and J. M. J. Fréchet, “In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 51, pp. 18264–18268, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus